05:03 PM EDT, 05/14/2024 (MT Newswires) -- Taysha Gene Therapies ( TSHA ) reported Q1 net loss Tuesday of $0.10 per diluted share, narrower from a loss of $0.28 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.11 per share.

Revenue for the quarter ended March 31 was $3.4 million, down from $4.7 million a year earlier. Analysts surveyed by Capital IQ expected $2.6 million.

The company said its cash and cash equivalents were $124 million as of March 31 and will support planned operating expenses and capital requirements into 2026.

The company's shares were down 3.5% in recent after-hours activity.

Price: 2.4800, Change: -0.09, Percent Change: -3.50